Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19 - 15/12/21

Doi : 10.1016/j.amjmed.2021.07.035

Charles H. Hennekens, MD, DrPH ^a,^⁎ , Manas Rane, MD ^b, Joshua Solano, MD ^c, Scott Alter, MD ^c, Heather Johnson, MD ^a,^d, Shiv Krishnaswamy, BS ^a, Richard Shih, MD ^c, Dennis Maki, MD ^e, David L. DeMets, PhD ^f
^a Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton
^b PGY-5, Harvard Medical School and Brigham and Women's Hospital and VA Boston Healthcare System, Boston, Mass
^c Department of Emergency Medicine, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton
^d Christine E. Lynn Women's Health &Wellness Institute, Boca Raton Regional Hospital/Baptist Health South Florida, Boca Raton
^e COVID-19 Intensive Care Unit, University of Wisconsin School of Medicine & Public Health, Madison
^f Biostatistics & Medical Informatics, University of Wisconsin-Madison School of Medicine & Public Health, Madison

^⁎Requests for reprints should be addressed to Charles H. Hennekens, MD, DrPH, Charles E. Schmidt College of Medicine, Florida Atlantic University, 2800 S. Ocean Blvd. PHA, Boca Raton, FL 33432.Charles E. Schmidt College of MedicineFlorida Atlantic University2800 S. Ocean Blvd. PHABoca RatonFL33432

Le texte complet de cet article est disponible en PDF.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Le texte complet de cet article est disponible en PDF.

Plan

Hydroxychloroquine in Post-Exposure Prophylaxis

Hydroxychloroquine in Hospitalized Patients

Meta-Analyses of Hydroxychloroquine in Post-Exposure Prophylaxis and COVID-19 Hospitalizations

Conclusion

	Funding: None.
	Conflicts of Interest: CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as Chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; to the Collaborative Institutional Training Initiative (CITI), legal counsel for Pfizer, the United States Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company. DLD reports that he is partially supported by a National Institutes of Health grant to the University of Wisconsin for the Clinical Translational Science Award for statistical consultation and collaboration and administrative leadership, serves or has recently served as an independent biostatistician in an advisory role to investigators and sponsors, often as a member of independent DSMBs for Actelion, Amgen, Astellas, AstraZeneca, Biotronik, Boehringer-Ingelheim, CVRx, Genentech, GlaxoSmithKline, Novartis, Merck, Pfizer, Roche, Sanofi Aventis, Takeda, Millennium, the Duke Clinical Research Institute, the Population Health Research Institute of McMaster University, and Harvard Partner's; receives royalties from publishers of the 3 textbooks that he has coauthored and edited; has tax-sheltered retirement accounts in mutual funds with Fidelity and Morgan Stanley; and has a small account of stock with Intel. All other authors report no disclosures.
	Authorship: All authors have participated in the preparation of the manuscript.